Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925598 | 0.85 | HIF1A (0.33) | HIF1AALDH1A1MAPT | |
| SCHEMBL5534700 | 0.73 | HIF1A (0.32) | HIF1AMAPT | |
| SCHEMBL14898029 | 0.72 | RXRA (0.50) | MEN1ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL960318 | 0.70 | MAPT (0.46) | NPC1ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL30044913 | 0.70 | ALDH1A1 (0.42) | MEN1ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL13018533 | 0.69 | CTSB (0.42) | — | |
| SCHEMBL14898033 | 0.69 | KDM4E (0.50) | HIF1AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL23705275 | 0.69 | NPC1 (0.41) | MEN1NPC1ALDH1A1MAPTHTT | |
| SCHEMBL829418 | 0.68 | GNG2 (0.40) | MEN1ALDH1A1MAPTKMT2ARXRA | |
| SCHEMBL7580541 | 0.68 | BLM (0.41) | LMNARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-7776895-B2 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2042168-A1 | Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2039700-A2 | Novel anti-inflammatory androstane derivatives | Glaxo Group Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20060287389-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20060287286-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| US-7144908-B2 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-7135600-B2 | Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis | GLAXO GROUP LIMITED (GB) | 2006-11-14 | — | — | US | disclosed |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | US | disclosed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| US-20050054622-A1 | Novel anti-inflammatory androstane derivatives | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040248867-A1 | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives | GLAXO GROUP LIMITED (GB) | 2004-12-09 | — | — | US | disclosed |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287389-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | PHOSPHO1, PNMT, PEBP1 | HIF1A 574/4885MEN1 1655/4885NPC1 1351/4885 |
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | NR5A1, HSD17B7, HSD17B1 | HIF1A 910/4885MEN1 4075/4885NPC1 2139/4885 |
| US-20040248867-A1 | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives | HSD17B1, NR5A1, HSD17B7 | HIF1A 853/4885MEN1 4431/4885NPC1 1942/4885 |
| US-20050209338-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | HIF1A 574/4885MEN1 1655/4885NPC1 1351/4885 |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | ADRB1, ADRB2, ADRA1A | HIF1A 403/4885MEN1 3712/4885NPC1 1272/4885 |
| US-20060287286-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | PHOSPHO1, PNMT, PEBP1 | HIF1A 574/4885MEN1 1655/4885NPC1 1351/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | HIF1A 1179/4885MEN1 3658/4885NPC1 2673/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | HIF1A 1388/4885MEN1 1526/4885NPC1 1613/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | HIF1A 574/4885MEN1 1655/4885NPC1 1351/4885 |
| US-20050054622-A1 | Novel anti-inflammatory androstane derivatives | NR5A1, HSD3B2, HSD3B1 | HIF1A 438/4885MEN1 4400/4885NPC1 1884/4885 |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | PNMT, CHRM3, HRH4 | HIF1A 254/4885MEN1 3525/4885NPC1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.